NeM0ooo
2021-11-20
Like
Bristol Myers Stock Keeps Skidding on FDA Heart Drug Review<blockquote>百时美施贵宝股价因 FDA 心脏药物审查而持续下滑</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
7
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":872041487,"tweetId":"872041487","gmtCreate":1637380791968,"gmtModify":1637380792157,"author":{"id":4091976027440070,"idStr":"4091976027440070","authorId":4091976027440070,"authorIdStr":"4091976027440070","name":"NeM0ooo","avatar":"https://static.tigerbbs.com/fc945b6e362666c4cb11d3c9b09018e8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":10,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Like</p></body></html>","htmlText":"<html><head></head><body><p>Like</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/872041487","repostId":1111549440,"repostType":4,"repost":{"id":"1111549440","kind":"news","pubTimestamp":1637372002,"share":"https://www.laohunote.com/m/news/1111549440?lang=zh_CN&edition=full","pubTime":"2021-11-20 09:33","market":"us","language":"en","title":"Bristol Myers Stock Keeps Skidding on FDA Heart Drug Review<blockquote>百时美施贵宝股价因 FDA 心脏药物审查而持续下滑</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111549440","media":"The Street","summary":"$Bristol Myers Squibb (BMY)$ shares fell Friday after the pharmaceutical titan said the FDA has exte","content":"<p>$Bristol Myers Squibb (<b>BMY</b>)$ shares fell Friday after the pharmaceutical titan said the FDA has extended its review of heart drug mavacamten for three months, until April 28.</p><p><blockquote>百时美施贵宝 (<b>宝马</b>)$ 周五，这家制药巨头表示 FDA 已将心脏病药物 mavacamten 的审查延长三个月，至 4 月 28 日，该公司股价下跌。</blockquote></p><p> The drug treats symptomatic obstructive hypertrophic cardiomyopathy (oHCM).</p><p><blockquote>该药物治疗有症状的梗阻性肥厚型心肌病（oHCM）。</blockquote></p><p> The Food and Drug Administration notified Bristol Thursday of the extension “to allow sufficient time to review information pertaining to updates to the proposed Risk Evaluation Mitigation Strategy (REMS),” the company said.</p><p><blockquote>该公司表示，美国食品和药物管理局周四通知布里斯托尔公司延期，“以便有足够的时间审查与拟议的风险评估缓解战略（REMS）更新相关的信息”。</blockquote></p><p> “A REMS program was included in the initial application for mavacamten. No additional data or studies have been requested.”</p><p><blockquote>“mavacamten 的初始申请中包含了 REMS 项目。目前尚未要求提供其他数据或研究。”</blockquote></p><p> Bristol Myers recently traded at $58.07, down 1.6%. It has slid 14% over the past three months.</p><p><blockquote>百时美施贵宝近期交易价格为 58.07 美元，下跌 1.6%。在过去的三个月里，它已经下滑了14%。</blockquote></p><p> “We are confident in the profile of mavacamten,” said Samit Hirawat, chief medical officer, global drug development at Bristol Myers.</p><p><blockquote>“百时美公司全球药物开发首席医疗官 Samit Hirawat 说：”我们对 mavacamten 的特性充满信心。</blockquote></p><p> “This first-in-class cardiac myosin inhibitor demonstrated clinically meaningful improvements in symptoms, functional status, and quality of life in symptomatic oHCM patients in the pivotal EXPLORER-HCM trial.”</p><p><blockquote>“在关键的EXPLORER-HCM试验中，这种一流的心脏肌球蛋白抑制剂在有症状的oHCM患者的症状、功能状态和生活质量方面显示出具有临床意义的改善。”</blockquote></p><p> Mavacamten represented the top potential drug of MyoKardia, which Bristol Myers acquired last year for $13.1 billion, MarketWatch reports.</p><p><blockquote>据 MarketWatch 报道，Mavacamten 是治疗心肌的最具潜力药物，百时美施贵宝去年以 131 亿美元收购了该药物。</blockquote></p><p> Morningstar analyst Damien Conover puts fair value for Bristol Myers at $68.</p><p><blockquote>晨星分析师 Damien Conover 认为百时美施贵宝的公允价值为 68 美元。</blockquote></p><p> “Bristol Myers hosted an investor day highlighting a strong pipeline that holds the potential to offset the firm’s major patent losses over the next decade, a key element supporting our wide moat rating,” he wrote in a commentary Tuesday.</p><p><blockquote>“他在周二的一篇评论中写道：”百时美公司举办了投资者日活动，强调了强大的产品线，有可能抵消公司未来十年的重大专利损失，这是支撑我们宽护城河评级的关键因素。</blockquote></p><p> “With most of the updates focused on still risky early-stage pipeline assets, the updates didn’t move our fair value estimate. However, we continue to view the stock as undervalued with the market not fully appreciating the firm’s late-stage pipeline.”</p><p><blockquote>“由于大多数更新都集中在风险仍然较高的早期管道资产上，因此这些更新并没有改变我们的公允价值估计。不过，我们仍然认为该股被低估，因为市场并未完全认识到该公司的后期管道资产。”</blockquote></p><p></p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers Stock Keeps Skidding on FDA Heart Drug Review<blockquote>百时美施贵宝股价因 FDA 心脏药物审查而持续下滑</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers Stock Keeps Skidding on FDA Heart Drug Review<blockquote>百时美施贵宝股价因 FDA 心脏药物审查而持续下滑</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Street</strong><span class=\"h-time small\">2021-11-20 09:33</span>\n</p>\n</h4>\n</header>\n<article>\n<p>$Bristol Myers Squibb (<b>BMY</b>)$ shares fell Friday after the pharmaceutical titan said the FDA has extended its review of heart drug mavacamten for three months, until April 28.</p><p><blockquote>百时美施贵宝 (<b>宝马</b>)$ 周五，这家制药巨头表示 FDA 已将心脏病药物 mavacamten 的审查延长三个月，至 4 月 28 日，该公司股价下跌。</blockquote></p><p> The drug treats symptomatic obstructive hypertrophic cardiomyopathy (oHCM).</p><p><blockquote>该药物治疗有症状的梗阻性肥厚型心肌病（oHCM）。</blockquote></p><p> The Food and Drug Administration notified Bristol Thursday of the extension “to allow sufficient time to review information pertaining to updates to the proposed Risk Evaluation Mitigation Strategy (REMS),” the company said.</p><p><blockquote>该公司表示，美国食品和药物管理局周四通知布里斯托尔公司延期，“以便有足够的时间审查与拟议的风险评估缓解战略（REMS）更新相关的信息”。</blockquote></p><p> “A REMS program was included in the initial application for mavacamten. No additional data or studies have been requested.”</p><p><blockquote>“mavacamten 的初始申请中包含了 REMS 项目。目前尚未要求提供其他数据或研究。”</blockquote></p><p> Bristol Myers recently traded at $58.07, down 1.6%. It has slid 14% over the past three months.</p><p><blockquote>百时美施贵宝近期交易价格为 58.07 美元，下跌 1.6%。在过去的三个月里，它已经下滑了14%。</blockquote></p><p> “We are confident in the profile of mavacamten,” said Samit Hirawat, chief medical officer, global drug development at Bristol Myers.</p><p><blockquote>“百时美公司全球药物开发首席医疗官 Samit Hirawat 说：”我们对 mavacamten 的特性充满信心。</blockquote></p><p> “This first-in-class cardiac myosin inhibitor demonstrated clinically meaningful improvements in symptoms, functional status, and quality of life in symptomatic oHCM patients in the pivotal EXPLORER-HCM trial.”</p><p><blockquote>“在关键的EXPLORER-HCM试验中，这种一流的心脏肌球蛋白抑制剂在有症状的oHCM患者的症状、功能状态和生活质量方面显示出具有临床意义的改善。”</blockquote></p><p> Mavacamten represented the top potential drug of MyoKardia, which Bristol Myers acquired last year for $13.1 billion, MarketWatch reports.</p><p><blockquote>据 MarketWatch 报道，Mavacamten 是治疗心肌的最具潜力药物，百时美施贵宝去年以 131 亿美元收购了该药物。</blockquote></p><p> Morningstar analyst Damien Conover puts fair value for Bristol Myers at $68.</p><p><blockquote>晨星分析师 Damien Conover 认为百时美施贵宝的公允价值为 68 美元。</blockquote></p><p> “Bristol Myers hosted an investor day highlighting a strong pipeline that holds the potential to offset the firm’s major patent losses over the next decade, a key element supporting our wide moat rating,” he wrote in a commentary Tuesday.</p><p><blockquote>“他在周二的一篇评论中写道：”百时美公司举办了投资者日活动，强调了强大的产品线，有可能抵消公司未来十年的重大专利损失，这是支撑我们宽护城河评级的关键因素。</blockquote></p><p> “With most of the updates focused on still risky early-stage pipeline assets, the updates didn’t move our fair value estimate. However, we continue to view the stock as undervalued with the market not fully appreciating the firm’s late-stage pipeline.”</p><p><blockquote>“由于大多数更新都集中在风险仍然较高的早期管道资产上，因此这些更新并没有改变我们的公允价值估计。不过，我们仍然认为该股被低估，因为市场并未完全认识到该公司的后期管道资产。”</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/investing/bristol-myers-heart-drug-mavacamten-gets-extended-fda-review\">The Street</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"source_url":"https://www.thestreet.com/investing/bristol-myers-heart-drug-mavacamten-gets-extended-fda-review","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111549440","content_text":"$Bristol Myers Squibb (BMY)$ shares fell Friday after the pharmaceutical titan said the FDA has extended its review of heart drug mavacamten for three months, until April 28.\nThe drug treats symptomatic obstructive hypertrophic cardiomyopathy (oHCM).\nThe Food and Drug Administration notified Bristol Thursday of the extension “to allow sufficient time to review information pertaining to updates to the proposed Risk Evaluation Mitigation Strategy (REMS),” the company said.\n“A REMS program was included in the initial application for mavacamten. No additional data or studies have been requested.”\nBristol Myers recently traded at $58.07, down 1.6%. It has slid 14% over the past three months.\n“We are confident in the profile of mavacamten,” said Samit Hirawat, chief medical officer, global drug development at Bristol Myers.\n“This first-in-class cardiac myosin inhibitor demonstrated clinically meaningful improvements in symptoms, functional status, and quality of life in symptomatic oHCM patients in the pivotal EXPLORER-HCM trial.”\nMavacamten represented the top potential drug of MyoKardia, which Bristol Myers acquired last year for $13.1 billion, MarketWatch reports.\nMorningstar analyst Damien Conover puts fair value for Bristol Myers at $68.\n“Bristol Myers hosted an investor day highlighting a strong pipeline that holds the potential to offset the firm’s major patent losses over the next decade, a key element supporting our wide moat rating,” he wrote in a commentary Tuesday.\n“With most of the updates focused on still risky early-stage pipeline assets, the updates didn’t move our fair value estimate. However, we continue to view the stock as undervalued with the market not fully appreciating the firm’s late-stage pipeline.”","news_type":1,"symbols_score_info":{"BMY":0.9}},"isVote":1,"tweetType":1,"viewCount":500,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/872041487"}
精彩评论